Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study
Summary: Background: Insufficient long-term data are available on antibody kinetics in survivors of Ebola virus disease (EVD). Likewise, few studies, with very small sample sizes, have investigated cross-reactions between Ebolavirus spp. In this study, we aimed to assess the humoral antibody respon...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/708b31ffbff24a4484bb0cc539035b8c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:708b31ffbff24a4484bb0cc539035b8c |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 Microbiology QR1-502 |
| spellingShingle |
Medicine (General) R5-920 Microbiology QR1-502 Mamadou Saliou Kalifa Diallo, MSc Ahidjo Ayouba, PhD Alpha Kabinet Keita, PhD Guillaume Thaurignac, MSc Mamadou Saliou Sow, MD Cécé Kpamou, MSc Thierno Alimou Barry, MD Philippe Msellati, PhD Jean-François Etard, PhD Martine Peeters, PhD René Ecochard, ProfPhD Eric Delaporte, ProfPhD Abdoulaye Toure, PhD Ahidjo Ayouba Sylvain Baize Kaba Bangoura Alimou Barry Moumié Barry Mamoudou Cissé Mohammed Cissé Eric Delaporte Jean-François Delfraissy Christelle Delmas Alice Desclaux Saliou Bella Diallo Mamadou Safiatou Diallo Mariama Sadjo Diallo Jean-François Étard Cécile Etienne Ousmane Faye Ibrahima Fofana Bruno Granouillac Suzanne Izard Djenaba Kassé Alpha Kabinet Keita Sakoba Keita Lamine Koivogui Cécé Kpamou Christine Lacarabaratz Sandrine Leroy Claire Levy Marchal Yves Levy N'Fally Magassouba Laura March Vincent Mendiboure Philippe Msellati Harissatou Niane Martine Peeters Yves-Marie Pers Hervé Raoul Sidi Lamine Sacko Ibrahima Savané Mamadou Saliou Sow Bernard Taverne Abdoulaye Touré Fodé Amara Traoré Falaye Traoré Yamoussa Youla Yazdan Yazdanpanah Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study |
| description |
Summary: Background: Insufficient long-term data are available on antibody kinetics in survivors of Ebola virus disease (EVD). Likewise, few studies, with very small sample sizes, have investigated cross-reactions between Ebolavirus spp. In this study, we aimed to assess the humoral antibody response and its determinants in survivors of EVD and assess cross-reactivity of antibodies between diverse Ebolavirus spp. Methods: In this observational, prospective cohort study, we collected blood samples from patients from three recruitment sites in Guinea included in the Postebogui study, and we assessed IgG antibody binding to recombinant glycoprotein, nucleoprotein, and 40-kDa viral protein (VP40) of Zaire (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) Ebolaviruses. Participants from the PostEbogui study, from whom we had at least one blood sample that could be tested for the presence of antibodies, were eligible for this analysis. Patients in the PostEbogui study were assessed clinically at inclusion, 1 month and 3 months later, and subsequently every 6 months for up to 60 months after discharge from the Ebola treatment centre. We explored predictors of glycoprotein, nucleoprotein, and VP40 antibody concentrations through a linear mixed model. A logistic mixed model was done to estimate the probability of seropositivity and associated determinants. We assessed cross-reactivity by use of hierarchical cluster analysis. Findings: Of the 802 patients included in the Postebogui study, 687 were included in our analyses. 310 (45%) patients were men and 377 (55%) were women, with an overall median age at the time of the first blood sample of 27·3 years (IQR 19·5–38·2). We observed an overall significant decrease over time of EBOV antibodies, with antibodies against nucleoproteins decreasing more rapidly. At 60 months after discharge from the Ebola treatment centre, the probability of having antibodies against glycoproteins was 76·2% (95% CI 67·2–83·3), against nucleoproteins was 59·4% (46·3–71·3), and against VP40 was 60·9% (51·4–69·8). Persistence of EBOV RNA in semen was associated with higher concentrations of IgG antibodies against nucleoprotein EBOV antigens. Individually, we observed in some survivors an antibody wax-and-wane pattern. The proportion of cross-reactions was highest between glycoproteins from Kissidougou and Mayinga EBOV strains (94·5%, 95% CI 92·5–96·1), followed by EBOV VP40 and BDBV VP40 (88·3%, 85·7–90·6), and EBOV VP40 and SUDV VP40 (83·3%, 80·3–86·1). Interpretation: The probability for survivors of EVD to have antibodies against one or more EBOV antigens remained high, although approximately 25% of survivors had undetectable antibodies, which could have implications, such as a possible decreasing population immunity, for future Ebola outbreaks in the same region. Funding: Reacting–Institut National de la Santé et de la Recherche Médicale, Institut de Recherche pour le Developpement, and Montpellier Université d'Excellence. |
| format |
article |
| author |
Mamadou Saliou Kalifa Diallo, MSc Ahidjo Ayouba, PhD Alpha Kabinet Keita, PhD Guillaume Thaurignac, MSc Mamadou Saliou Sow, MD Cécé Kpamou, MSc Thierno Alimou Barry, MD Philippe Msellati, PhD Jean-François Etard, PhD Martine Peeters, PhD René Ecochard, ProfPhD Eric Delaporte, ProfPhD Abdoulaye Toure, PhD Ahidjo Ayouba Sylvain Baize Kaba Bangoura Alimou Barry Moumié Barry Mamoudou Cissé Mohammed Cissé Eric Delaporte Jean-François Delfraissy Christelle Delmas Alice Desclaux Saliou Bella Diallo Mamadou Safiatou Diallo Mariama Sadjo Diallo Jean-François Étard Cécile Etienne Ousmane Faye Ibrahima Fofana Bruno Granouillac Suzanne Izard Djenaba Kassé Alpha Kabinet Keita Sakoba Keita Lamine Koivogui Cécé Kpamou Christine Lacarabaratz Sandrine Leroy Claire Levy Marchal Yves Levy N'Fally Magassouba Laura March Vincent Mendiboure Philippe Msellati Harissatou Niane Martine Peeters Yves-Marie Pers Hervé Raoul Sidi Lamine Sacko Ibrahima Savané Mamadou Saliou Sow Bernard Taverne Abdoulaye Touré Fodé Amara Traoré Falaye Traoré Yamoussa Youla Yazdan Yazdanpanah |
| author_facet |
Mamadou Saliou Kalifa Diallo, MSc Ahidjo Ayouba, PhD Alpha Kabinet Keita, PhD Guillaume Thaurignac, MSc Mamadou Saliou Sow, MD Cécé Kpamou, MSc Thierno Alimou Barry, MD Philippe Msellati, PhD Jean-François Etard, PhD Martine Peeters, PhD René Ecochard, ProfPhD Eric Delaporte, ProfPhD Abdoulaye Toure, PhD Ahidjo Ayouba Sylvain Baize Kaba Bangoura Alimou Barry Moumié Barry Mamoudou Cissé Mohammed Cissé Eric Delaporte Jean-François Delfraissy Christelle Delmas Alice Desclaux Saliou Bella Diallo Mamadou Safiatou Diallo Mariama Sadjo Diallo Jean-François Étard Cécile Etienne Ousmane Faye Ibrahima Fofana Bruno Granouillac Suzanne Izard Djenaba Kassé Alpha Kabinet Keita Sakoba Keita Lamine Koivogui Cécé Kpamou Christine Lacarabaratz Sandrine Leroy Claire Levy Marchal Yves Levy N'Fally Magassouba Laura March Vincent Mendiboure Philippe Msellati Harissatou Niane Martine Peeters Yves-Marie Pers Hervé Raoul Sidi Lamine Sacko Ibrahima Savané Mamadou Saliou Sow Bernard Taverne Abdoulaye Touré Fodé Amara Traoré Falaye Traoré Yamoussa Youla Yazdan Yazdanpanah |
| author_sort |
Mamadou Saliou Kalifa Diallo, MSc |
| title |
Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study |
| title_short |
Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study |
| title_full |
Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study |
| title_fullStr |
Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study |
| title_full_unstemmed |
Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study |
| title_sort |
temporal evolution of the humoral antibody response after ebola virus disease in guinea: a 60-month observational prospective cohort study |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/708b31ffbff24a4484bb0cc539035b8c |
| work_keys_str_mv |
AT mamadousalioukalifadiallomsc temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT ahidjoayoubaphd temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT alphakabinetkeitaphd temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT guillaumethaurignacmsc temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT mamadousaliousowmd temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT cecekpamoumsc temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT thiernoalimoubarrymd temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT philippemsellatiphd temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT jeanfrancoisetardphd temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT martinepeetersphd temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT reneecochardprofphd temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT ericdelaporteprofphd temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT abdoulayetourephd temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT ahidjoayouba temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT sylvainbaize temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT kababangoura temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT alimoubarry temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT moumiebarry temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT mamoudoucisse temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT mohammedcisse temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT ericdelaporte temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT jeanfrancoisdelfraissy temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT christelledelmas temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT alicedesclaux temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT salioubelladiallo temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT mamadousafiatoudiallo temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT mariamasadjodiallo temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT jeanfrancoisetard temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT cecileetienne temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT ousmanefaye temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT ibrahimafofana temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT brunogranouillac temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT suzanneizard temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT djenabakasse temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT alphakabinetkeita temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT sakobakeita temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT laminekoivogui temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT cecekpamou temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT christinelacarabaratz temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT sandrineleroy temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT clairelevymarchal temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT yveslevy temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT nfallymagassouba temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT lauramarch temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT vincentmendiboure temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT philippemsellati temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT harissatouniane temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT martinepeeters temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT yvesmariepers temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT herveraoul temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT sidilaminesacko temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT ibrahimasavane temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT mamadousaliousow temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT bernardtaverne temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT abdoulayetoure temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT fodeamaratraore temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT falayetraore temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT yamoussayoula temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy AT yazdanyazdanpanah temporalevolutionofthehumoralantibodyresponseafterebolavirusdiseaseinguineaa60monthobservationalprospectivecohortstudy |
| _version_ |
1718400657158832128 |
| spelling |
oai:doaj.org-article:708b31ffbff24a4484bb0cc539035b8c2021-12-02T05:03:50ZTemporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study2666-524710.1016/S2666-5247(21)00170-1https://doaj.org/article/708b31ffbff24a4484bb0cc539035b8c2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666524721001701https://doaj.org/toc/2666-5247Summary: Background: Insufficient long-term data are available on antibody kinetics in survivors of Ebola virus disease (EVD). Likewise, few studies, with very small sample sizes, have investigated cross-reactions between Ebolavirus spp. In this study, we aimed to assess the humoral antibody response and its determinants in survivors of EVD and assess cross-reactivity of antibodies between diverse Ebolavirus spp. Methods: In this observational, prospective cohort study, we collected blood samples from patients from three recruitment sites in Guinea included in the Postebogui study, and we assessed IgG antibody binding to recombinant glycoprotein, nucleoprotein, and 40-kDa viral protein (VP40) of Zaire (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) Ebolaviruses. Participants from the PostEbogui study, from whom we had at least one blood sample that could be tested for the presence of antibodies, were eligible for this analysis. Patients in the PostEbogui study were assessed clinically at inclusion, 1 month and 3 months later, and subsequently every 6 months for up to 60 months after discharge from the Ebola treatment centre. We explored predictors of glycoprotein, nucleoprotein, and VP40 antibody concentrations through a linear mixed model. A logistic mixed model was done to estimate the probability of seropositivity and associated determinants. We assessed cross-reactivity by use of hierarchical cluster analysis. Findings: Of the 802 patients included in the Postebogui study, 687 were included in our analyses. 310 (45%) patients were men and 377 (55%) were women, with an overall median age at the time of the first blood sample of 27·3 years (IQR 19·5–38·2). We observed an overall significant decrease over time of EBOV antibodies, with antibodies against nucleoproteins decreasing more rapidly. At 60 months after discharge from the Ebola treatment centre, the probability of having antibodies against glycoproteins was 76·2% (95% CI 67·2–83·3), against nucleoproteins was 59·4% (46·3–71·3), and against VP40 was 60·9% (51·4–69·8). Persistence of EBOV RNA in semen was associated with higher concentrations of IgG antibodies against nucleoprotein EBOV antigens. Individually, we observed in some survivors an antibody wax-and-wane pattern. The proportion of cross-reactions was highest between glycoproteins from Kissidougou and Mayinga EBOV strains (94·5%, 95% CI 92·5–96·1), followed by EBOV VP40 and BDBV VP40 (88·3%, 85·7–90·6), and EBOV VP40 and SUDV VP40 (83·3%, 80·3–86·1). Interpretation: The probability for survivors of EVD to have antibodies against one or more EBOV antigens remained high, although approximately 25% of survivors had undetectable antibodies, which could have implications, such as a possible decreasing population immunity, for future Ebola outbreaks in the same region. Funding: Reacting–Institut National de la Santé et de la Recherche Médicale, Institut de Recherche pour le Developpement, and Montpellier Université d'Excellence.Mamadou Saliou Kalifa Diallo, MScAhidjo Ayouba, PhDAlpha Kabinet Keita, PhDGuillaume Thaurignac, MScMamadou Saliou Sow, MDCécé Kpamou, MScThierno Alimou Barry, MDPhilippe Msellati, PhDJean-François Etard, PhDMartine Peeters, PhDRené Ecochard, ProfPhDEric Delaporte, ProfPhDAbdoulaye Toure, PhDAhidjo AyoubaSylvain BaizeKaba BangouraAlimou BarryMoumié BarryMamoudou CisséMohammed CisséEric DelaporteJean-François DelfraissyChristelle DelmasAlice DesclauxSaliou Bella DialloMamadou Safiatou DialloMariama Sadjo DialloJean-François ÉtardCécile EtienneOusmane FayeIbrahima FofanaBruno GranouillacSuzanne IzardDjenaba KasséAlpha Kabinet KeitaSakoba KeitaLamine KoivoguiCécé KpamouChristine LacarabaratzSandrine LeroyClaire Levy MarchalYves LevyN'Fally MagassoubaLaura MarchVincent MendibourePhilippe MsellatiHarissatou NianeMartine PeetersYves-Marie PersHervé RaoulSidi Lamine SackoIbrahima SavanéMamadou Saliou SowBernard TaverneAbdoulaye TouréFodé Amara TraoréFalaye TraoréYamoussa YoulaYazdan YazdanpanahElsevierarticleMedicine (General)R5-920MicrobiologyQR1-502ENThe Lancet Microbe, Vol 2, Iss 12, Pp e676-e684 (2021) |